What is Aurinia Pharmaceuticals Inc. (AUPH)?

Aurinia Pharmaceuticals Inc. (AUPH) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of AUPH?

The current price of AUPH is $16.13. Prices are updated in real time on Stocks360.

What is AUPH's price-to-earnings (PE) ratio?

AUPH's trailing twelve-month PE ratio is 6.83, based on current price and earnings per share data available on Stocks360.

What is AUPH's market capitalization?

AUPH's market capitalization is $2,074,350,260.00, placing it in the mid-cap tier.

Aurinia Pharmaceuticals Inc. (AUPH)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$16.13

Market Cap

$2.07B

PE (TTM)

6.83

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.41

Day Range

$15.98 – $16.35

52-wk Range

$10.34 – $19.25

Avg Volume

N/A

Volume

941.98K

Aurinia Pharmaceuticals Inc. (AUPH) is a publicly traded company in the Healthcare sector. Latest price: $16.13. Market cap $2.07B. Trailing PE 6.83. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-09-16 · $12.52 2026-09-15 · $16.13 (+28.83%)

Earnings

Most Recent

Aug 6, 2026

EPS $0.28 vs est. $0.24

Beat by $0.04

Next Earnings

Nov 3, 2026

EPS estimate $0.21

Proprietary Signals

Signal snapshot temporarily unavailable.

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	6.83×
P/S (TTM)	6.66×
P/B	3.41×
PEG	0.02×
P/FCF (TTM)	11.95×
EV / EBITDA	10.39×
EV / Sales	6.28×
Earnings Yield	14.97%
Free Cash Flow Yield	8.37%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.95B
Revenue (TTM)	$311.51M
Net Income (TTM)	$310.54M
Free Cash Flow (TTM)	$190.17M
Net Debt	-$119.41M
Working Capital	$441.43M
Gross Margin	90.36%
Operating Margin	48.39%
Net Margin	100.84%
Return on Equity	59.00%
Return on Invested Capital	21.27%